SCHEMBL12723908

SCHEMBL12723908

CCOP(=O)(OCC)c1c(N)cccc1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.39
NPSR1 Q6W5P4 2/20 0.39
TSHR P16473 2/20 0.39
ALOX15 P16050 1/20 0.39
MAPK1 P28482 1/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
CA2 P00918 3/20 0.38
CA12 O43570 2/20 0.38
CA1 P00915 2/20 0.38
CA9 Q16790 2/20 0.38
CA4 P22748 1/20 0.38
CA5A P35218 1/20 0.38
CA7 P43166 1/20 0.38
CA5B Q9Y2D0 1/20 0.38
ALDH1A1 P00352 4/20 0.34
KCNH2 Q12809 1/20 0.34
KDM4E B2RXH2 2/20 0.34
HSD17B10 Q99714 2/20 0.34
GLA P06280 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL577670 0.88 MEN1 (0.42) HPGDNPSR1TSHRALOX15MAPK1
SCHEMBL1629819 0.81 CD44 (0.39) HPGDNPSR1TSHRALOX15MAPK1
SCHEMBL12723910 0.77 MEN1 (0.48) HPGDNPSR1TSHRALOX15MAPK1
SCHEMBL24596872 0.74 HDAC1 (0.37) HPGDTSHRALOX15MEN1KMT2A
SCHEMBL29468629 0.72 MEN1 (0.53) HPGDNPSR1TSHRALOX15MAPK1
SCHEMBL780087 0.72 MEN1 (0.53) HPGDNPSR1TSHRALOX15MAPK1
SCHEMBL641441 0.72 MEN1 (0.53) HPGDNPSR1MEN1KMT2ACA2
SCHEMBL28672462 0.71 MEN1 (0.49) HPGDNPSR1TSHRMEN1KMT2A
SCHEMBL29227263 0.71 HDAC1 (0.37) HPGDTSHRMAPK1MEN1KMT2A
SCHEMBL776821 0.68 MEN1 (0.45) HPGDNPSR1TSHRALOX15MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932240-B2 Phosphadiazine HCV polymerase inhibitors IV IDENIX PHARMACEUTICALS, INC. (US) 2011-04-26 US disclosed
US-7932240-B2 Phosphadiazine HCV polymerase inhibitors IV IDENIX PHARMACEUTICALS, INC. (US) 2011-04-26 US disclosed
US-20090081158-A1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV IDENIX PHARMACEUTICALS, INC. (US) 2009-03-26 US disclosed
US-20090081158-A1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV IDENIX PHARMACEUTICALS, INC. (US) 2009-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090081158-A1 PHOSPHADIAZINE HCV POLYMERASE INHIBITORS IV POLI, ITPA, POLR2H HPGD 1074/4885NPSR1 4168/4885TSHR 3605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.